Could a mushroom-derived product be the future of lung cancer prevention?

  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 34 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 71%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Researchers find that a mushroom-derived product, GLSF, shows promise in reducing lung toxicity and tumor development induced by tobacco smoke carcinogens in mice. The study opens the door for future clinical trials, potentially offering a natural preventive measure against lung cancer.

By Susha Cheriyedath, M.Sc.Sep 26 2023 In a preclinical study published in the journal Frontiers in Pharmacology, researchers from the USA investigated the potential chemopreventive effects of a mushroom - Ganoderma lucidum -derived commercial product named GLSF in vitro and in mice with lung carcinogenesis induced by two tobacco smoke carcinogens, namely benzo[a]pyrene and 4--1--1-butanone .

A medicinal mushroom, GL is known to have anticancer and immunomodulating properties and has been employed as a nutraceutical in the treatment of various chronic ailments, including cancer. However, the effects of GL or GL-derived products have not been studied for the prevention of tobacco-smoking-induced lung carcinogenesis.

Results and discussion In the in vitro experiments, GLSF was found to inhibit the BPDE-induced transformation of BEAS-2B cells, indicating its potential role in controlling the cellular alterations resulting from the exposure of these bronchial epithelial cells to known carcinogens. The findings corroborate with existing literature.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 19. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Researchers crack genetic code of rare kidney cancerThe genetic code of a rare form of kidney cancer, called reninoma, has been studied for the first time. In a paper, published in Nature Communications, researchers at the Wellcome Sanger Institute, Great Ormond Street Hospital and The Royal Free Hospital also revealed a new drug target that could serve as an alternative treatment if surgery is not recommended.
Source: medical_xpress - 🏆 101. / 51 Read more »

Researchers crack the genetic code of rare form of kidney cancerThe genetic code of a rare form of kidney cancer, called reninoma, has been studied for the first time. In the new paper, published today (25th September) in Nature Communications, researchers at the Wellcome Sanger Institute, Great Ormond Street Hospital and The Royal Free Hospital also revealed a new drug target that could serve as an alternative treatment if surgery is not recommended.
Source: NewsMedical - 🏆 19. / 71 Read more »

Researchers show how a small strand of RNA is key to fighting cancerA team of researchers at the University of Massachusetts Amherst has shown that a single, small strand of microRNA, or miRNA, known as let-7, governs the ability of T-cells to recognize and remember tumor cells. This cellular memory is the basis for how vaccines work. Boosting cellular memory to recognize tumors could help improve cancer therapies.
Source: medical_xpress - 🏆 101. / 51 Read more »

Medical researchers tackle immune rejection of biomedical implantsTo learn more about what causes the body to reject biomedical implants, a team at the University of Arizona College of Medicine-Tucson identified a protein that appears to help drive this response, and hopes their discoveries will improve the design and safety of biomedical implants. The findings were published today in Nature Biomedical Engineering.
Source: medical_xpress - 🏆 101. / 51 Read more »